Objectives: Higher circulating omega-3 fatty acids (n-3 FAs) are associated with a lower prevalence of anti-CCP antibodies and RF in subjects without RA. We examined whether, in anti-CCP+ subjects, n-3 FAs also play a role in development of inflammatory arthritis (IA). Methods: At Colorado-based health fairs from 2008 to 2014, participants without a previous diagnosis of RA who were anti-CCP3+ (n = 47) were recruited into a follow-up study; symptom assessments and joint examinations were conducted every 6 months for the determination of IA. We measured n-3 FAs as a percentage of total lipids in red blood cell membranes (n-3 FA%) at each visit. Results: We detected IA in 10 anti-CCP3+ subjects (21%) at the baseline visit. Increased total n-3 FA% in red blood cell membranes [odds ratio (OR) = 0.09, 95% CI: 0.01, 0.76], specifically docosapentaenoic acid (OR = 0.16, 95% CI: 0.03, 0.83) and docosahexaenoic acid (OR = 0.23, 95% CI: 0.06, 0.86), was associated with a lower odds of IA at the baseline visit, adjusting for n-3 FA supplement use, current smoking, RF+, elevated CRP+ and shared epitope. We followed 35 of the anti-CCP3+ subjects who were IA negative at baseline and detected 14 incident IA cases over an average of 2.56 years of follow-up. In a time-varying survival analysis, increasing docosapentaenoic acid significantly decreased risk of incident IA (hazard ratio = 0.52, 95% CI: 0.27, 0.98), adjusting for age at baseline, n-3 FA supplement use, RF+, CRP+ and shared epitope. Conclusion: n-3 FAs may potentially lower the risk of transition from anti-CCP positivity to IA, an observation that warrants further investigation.
Objectives: Higher circulating omega-3 fatty acids (n-3 FAs) are associated with a lower prevalence of anti-CCP antibodies and RF in subjects without RA. We examined whether, in anti-CCP+ subjects, n-3 FAs also play a role in development of inflammatory arthritis (IA). Methods: At Colorado-based health fairs from 2008 to 2014, participants without a previous diagnosis of RA who were anti-CCP3+ (n = 47) were recruited into a follow-up study; symptom assessments and joint examinations were conducted every 6 months for the determination of IA. We measured n-3 FAs as a percentage of total lipids in red blood cell membranes (n-3 FA%) at each visit. Results: We detected IA in 10 anti-CCP3+ subjects (21%) at the baseline visit. Increased total n-3 FA% in red blood cell membranes [odds ratio (OR) = 0.09, 95% CI: 0.01, 0.76], specifically docosapentaenoic acid (OR = 0.16, 95% CI: 0.03, 0.83) and docosahexaenoic acid (OR = 0.23, 95% CI: 0.06, 0.86), was associated with a lower odds of IA at the baseline visit, adjusting for n-3 FA supplement use, current smoking, RF+, elevated CRP+ and shared epitope. We followed 35 of the anti-CCP3+ subjects who were IA negative at baseline and detected 14 incident IA cases over an average of 2.56 years of follow-up. In a time-varying survival analysis, increasing docosapentaenoic acid significantly decreased risk of incident IA (hazard ratio = 0.52, 95% CI: 0.27, 0.98), adjusting for age at baseline, n-3 FA supplement use, RF+, CRP+ and shared epitope. Conclusion:n-3 FAs may potentially lower the risk of transition from anti-CCP positivity to IA, an observation that warrants further investigation.
Authors: Wooki Kim; Naim A Khan; David N McMurray; Ian A Prior; Naisyin Wang; Robert S Chapkin Journal: Prog Lipid Res Date: 2010-02-20 Impact factor: 16.195
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Ryan W Gan; Leendert A Trouw; Jing Shi; René E M Toes; Tom W J Huizinga; M Kristen Demoruelle; Jason R Kolfenbach; Gary O Zerbe; Kevin D Deane; Jess D Edison; William R Gilliland; Jill M Norris; V Michael Holers Journal: J Rheumatol Date: 2015-01-15 Impact factor: 4.666
Authors: Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin O'Donnell; Michael H Weisman; Jane H Buckner; Vivian H Gersuk; Shan Wei; Ted R Mikuls; James O'Dell; Peter K Gregersen; Richard M Keating; Jill M Norris; V Michael Holers Journal: Arthritis Rheum Date: 2009-12-15
Authors: Albert M Joensen; Erik B Schmidt; Claus Dethlefsen; Søren P Johnsen; Anne Tjønneland; Lars H Rasmussen; Kim Overvad Journal: Br J Nutr Date: 2009-10-14 Impact factor: 3.718
Authors: Susanna M Proudman; Michael J James; Llewellyn D Spargo; Robert G Metcalf; Thomas R Sullivan; Maureen Rischmueller; Katerina Flabouris; Mihir D Wechalekar; Anita T Lee; Leslie G Cleland Journal: Ann Rheum Dis Date: 2013-09-30 Impact factor: 19.103
Authors: Ryan W Gan; M Kristen Demoruelle; Kevin D Deane; Michael H Weisman; Jane H Buckner; Peter K Gregersen; Ted R Mikuls; James R O'Dell; Richard M Keating; Tasha E Fingerlin; Gary O Zerbe; Michael J Clare-Salzler; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2016-05-17 Impact factor: 27.973
Authors: Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg Journal: Front Immunol Date: 2022-06-30 Impact factor: 8.786
Authors: Kristen J Polinski; Elizabeth A Bemis; Fan Yang; Tessa Crume; M Kristen Demoruelle; Marie Feser; Jennifer Seifert; James R O'Dell; Ted R Mikuls; Michael H Weisman; Peter K Gregersen; Richard M Keating; Jane Buckner; Nichole Reisdorph; Kevin D Deane; Michael Clare-Salzler; V Michael Holers; Jill M Norris Journal: Arthritis Rheumatol Date: 2021-04-23 Impact factor: 15.483
Authors: Elizabeth A Bemis; M Kristen Demoruelle; Jennifer A Seifert; Kristen J Polinski; Michael H Weisman; Jane H Buckner; Peter K Gregersen; Ted R Mikuls; James R ODell; Richard M Keating; Kevin D Deane; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2020-09-14 Impact factor: 27.973